Introduction
Cytogenetic and molecular abnormalities are currently utilized to stratify acute myelogenous leukaemia (AML) into groups such as acute promyelocytic leukaemia, associated with t(15;17)/PML-RARa, or 'CBF leukaemias' such as t(8;21)/AML-ETO or inv(16)/CBFb-MYH11 (Marcucci et al., 2000) . The identification of recurrent translocations in AML has played an important role in making therapeutic decisions for the management of this heterogeneous disease, since the presence of these abnormalities can be an independent prognostic parameter for response and remission duration (Grimwade et al., 1998) . Although NC-AML is the most prevalent AML group, NC-AML is poorly understood and heterogeneous in terms of clinical and biological presentation and prognosis. Clearly, better molecular characterization is required to improve clinical management of these patients.
DNA microarray technology represents a promising tool to address the complexity of cancer (Bertucci et al., 2001) . This was first demonstrated by Golub et al. (1999) , who showed that AML and acute lymphoblastic leukaemia have distinct expression profiles. Subsequent studies have shown that AML groups defined by cytomorphology, immunophenotypics, or cytogenetics (Virtaneva et al., 2001; Schoch et al., 2002; Haferlach et al., 2003b; Kohlmann et al., 2003) can also be identified by gene expression profiling. Other important potential applications include the refinement of prognostic classes of tumours (Alizadeh et al., 2000; Bertucci et al., 2000; Yeoh et al., 2002) and enhanced understanding of the pathophysiologic signalling pathways involved in leukaemogenesis (Bertucci et al., 2001) .
Here, we report the analysis of mRNA expression of 9000 genes in adult AML (n ¼ 53) with normal and abnormal karyotype on DNA microarrays. Our objective was to determine whether gene expression profiling can identify prognostically distinct subgroups of NC-AML. In addition, we also describe the transcriptional alterations associated with trisomy 8, and FLT3 or MLL gene duplications.
Results

Gene expression profiling of adult AML and unsupervised hierarchical analysis
We analysed 36 samples with normal cytogenetics (NC-AMLs), six samples with trisomy 8 (tri8-AMLs), five samples with t(15;17) including the NB4 cell line, four samples with t(8;21) including the Kasumi cell line, three samples with t(11;19), and one with 7q deletion (del(7q)). Unsupervised hierarchical clustering was applied on the basis of genes with significant variation in expression level across all the experiments (2599 genes/expressed sequence tags (ESTs)). This exploratory approach allows to group genes and samples on the basis of similarity in their pattern of expression. Results are presented in Figure 1 in a colour-coded matrix. Three major sample clusters (referred to as I-III) were identified. We studied the correlations between these clusters and the major biological and clinical parameters. No significant correlation was found with age of patients, AML onset, FAB type, multilineage dysplasia, FLT3 or MLL status, and clinical outcome of patients. Interestingly, there was a significantly different distribution of hyperleucocytosis and cytogenetic data between the three clusters ( Figure 1b) . Patients with hyperleucocytosis (defined as a white blood cell count >30 Â 10 9 /l) represented 19% of patients in cluster I, 48% in cluster II, and 69% in cluster III (P ¼ 0.017, w 2 test). Remarkably, all samples with t(15;17) were grouped in cluster II, and all samples with t(11;19) and most of t(8;21) samples in cluster III (P ¼ 0.006, w 2 test). These results collectively suggested that specific expression profiles are associated with reciprocal translocations. On the other hand, NC-AMLs and tri8-AMLs were distributed across the three clusters, suggesting more heterogeneous expression profiles.
Supervised classification according to cytogenetic categories
We next used supervised analyses to identify the genes most specific of each cytogenetic category. We first compared four AML groups, the 36 NC-AMLs and the three groups with the aforementioned translocations (n ¼ 12). The gene expression pattern of each group was compared to that of three other ones combined, resulting in four comparisons. A gene was considered as more correlated to one group if it was found discriminator in one comparison (Po10 À3 , Student's t-test) but not in the three other ones. The expression profiles of the 10 most overexpressed genes (see Supplementary Table 2) per list were then aggregated and hierarchical clustering was applied (Figure 2a ). Three major sample clusters were identified. One cluster (20 samples, 'pure-NC' cluster) contained only NCAMLs. All t(11;19) samples were grouped in the same cluster, as well as the t(8;21) and t(15;17) samples, which were assigned to two related specific subclusters. The 36 NC-AMLs were either grouped within the 'pure-NC' cluster or distributed among the other clusters, further demonstrating their transcriptional heterogeneity. This suggested the existence of at least two subgroups of NC-AML: first, a homogeneous subgroup ('pure-NC'), and second, a more heterogeneous subgroup ('translocation like') with samples that share patterns of molecular alterations with other AML groups defined by a specific translocation.
We next compared the NC-AML cases with another heterogeneous group, that of tri8-AMLs. We identified 17 clones (including 14 genes) that discriminated NC-AML from tri8-AML (Po10 À4 , Student's t-test, Figure 2b ). All tri8-AML samples clustered together. Of 36 NC-AML samples, 14 displayed expression profiles closer to tri8-AMLs than to other NC-AML cases, further suggesting heterogeneity among these patients. Eight of the 17 discriminatory genes were overexpressed in the tri8 group and four mapped to chromosome 8. The median ratio of the expression level of these four genes in tri8-AML relative to NC-AML cases was 1.8 (range: 1.4-2.8). We confirmed this gene-dosage effect at the chromosomal level. For each chromosome, we computed the average ratio between the average expression level of corresponding genes in the tri8-AML samples and their average expression level in the NC-AML cases. Analysis was applied to 6738 genes/ESTs with expression detected in all samples, of which 6083 were mapped to a chromosome and 241 to chromosome 8. Tri8-AML samples exhibited significantly increased expression ( þ 13%) in genes mapped to chromosome 8 (Figure 2c Correlation between gene expression profiles and FLT3 or MLL tandem duplication in NC-AML samples A supervised approach was next applied to identify a gene expression signature (GES) correlated with relevant molecular abnormalities, such as FLT3 or MLL tandem duplications in the NC-AML samples.
AML samples with FLT3 internal tandem duplications (FLT3-ITD)
Among the 23 NC-AML cases tested by RT-PCR for the presence of FLT3-ITD, 10 (B43%) were FLT3-ITD. We identified a set of 45 genes/ESTs (Figure 3a ) that were significantly differentially expressed between the positive and negative samples (Po5 Â 10 À3 , Student's t-test). In all, 20 were overexpressed and 25 were underexpressed in FLT3-positive samples. Hierarchical clustering analysis successfully distinguished FLT3-positive from FLT3-negative samples in 21 of these 23 cases (Table 1) .
AML patients with MLL partial tandem duplications (MLL-PTD)
A similar approach was applied to assess MLL status. Four of 14 tested AML cases had MLL duplication. We identified 33 genes/ESTs with significantly differential expression between samples with (n ¼ 4) and without (n ¼ 10) MLL duplication (Po10 À4 , Student's t-test). Reclustering based on these clones accurately classified all samples according to MLL status (Figure 3b ).
Correlation between gene expression profiles and clinical outcome of NC-AML patients
We selected 24 NC-AML patients with necessary followup data to identify a GES associated with clinical are identified (I, green branches; II, blue branches; III, red branches). Samples are designated with numbers followed by their karyotype (NC, normal cytogenetics). Down, relevant clinicobiological features are represented according to a grey colour ladder (unavailable, oblique feature): age (o65 years, white; X65 years, black), AML onset (de novo, white; secondary, black), hyperleucocytosis (o30 G/l, white; X30 G/l, black), FAB type (M3, white; M1 or M2, grey; M4 or M5, black), multilineage dysplasia (no, white; yes, black), karyotype (t(8;21) or t(15;17), white; normal cytogenetics (NC) or trisomy 8 (tri8), grey; 7q deletion (del(7q)) or t(11;19), black), FLT3 (negative ITD and no mutation, white; positive ITD or mutation, black), MLL-PTD (negative, white; positive, black), and clinical outcome (continuous CR, white; relapse after CR, grey; refractory to induction therapy, black)
Gene expression profiling of acute myelogenous leukaemia N Vey et al outcome, including 11 patients alive in continuous complete clinical remission (CCR) for more than 24 months, and 13 patients with treatment failure (TF samples, including six cases refractory to induction chemotherapy and seven relapses after complete remission (CR)). We identified 43 genes/ESTs that discriminated between CCR and TF samples (Po3 Â 10 À3 , Student's t-test) using supervised analysis. These genes are listed in Table 2 . In all, 20 of them, including TOP2B, were overexpressed in CCR samples and 23 were underexpressed. Reclustering applied to these 43 genes distinguished two classes of samples designated I and II (Figure 4a ) with significantly different outcome (P ¼ 0.00001, Fisher's exact test): all 11 patients (100%) of class I experienced failure or relapse after induction therapy (poor prognosis class), while 11 out of 13 patients in class II (85%) survived for more than 24 months without relapse after CR (good prognosis class, Figure 4b ). Two patients with TF were misclassified. The major clinical and biological characteristics of patients in these two classes are listed in Table 3 . Patients in the poor prognosis class (class I) were significantly older than patients of the good prognosis class (class II), and showed an increased rate of dysplastic changes and therapy-related or secondary AMLs (P ¼ 0.03, Fisher's exact test).
Interestingly, there was a significant correlation between this classification and the subgroups of NCAMLs samples defined in Figure 2a , that is, 'pure-NC' or 'translocation like'. Of 13 samples, 11 from the good prognosis class (class II) were defined as 'translocation like', while eight of 11 samples from the poor prognosis class (class I) were defined as 'pure-NC' (P ¼ 0.01, Fisher's exact test).
Discussion
We have investigated the heterogeneity of AML at the transcriptional level. We identify specific patterns of gene expression underlying the heterogeneity of NC-AML, including response to chemotherapy.
Identification of NC-AML subgroups
We first compared the gene expression profiles of AML samples with normal cytogenetics and with t(15;17), t(8;21) and t(11;19). Although we classified these samples by using the expression profiles of genes most highly correlated to each of these four groups, we identified two subgroups of NC-AML: one subgroup (designated 'pure-NC') was homogeneous and exclusively contained NC-AML cases, whereas the second subgroup was heterogeneous and included AML patients harbouring various translocations. This suggests that some NC-AML cases are more similar to AML with translocations than to other NC-AML samples. At the transcriptional level, they behave as 'translocation-like' AML, and may therefore harbour alterations in the same signalling pathways or gene networks as those affected by the corresponding oncogenic gene fusions. The increased proportion of chemoresistant disease in the 'pure-NC' cluster further suggests that a correlation may exist between these subgroups and biological and clinical features. The present work is consistent with previous studies demonstrating that DNA microarray analyses can reliably discriminate between AML with different translocations (Schoch et al., 2002; Debernardi et al., 2003; Haferlach et al., 2003a; Kohlmann et al., 2003; Bullinger et al., 2004; Valk et al., 2004) . Some of these reports focused on the stratification of NC-AML (Debernardi et al., 2003; Kohlmann et al., 2003; Bullinger et al., 2004; Valk et al., 2004) . In two studies (Debernardi et al., 2003; Kohlmann et al., 2003) , the NC-AMLs group was homogeneous and the samples could not be subclassified probably because of the small number of NC-AML samples profiled in these studies. In contrast, and in agreement with our results, two recent reports that profiled more samples (45 and 119, respectively) demonstrated the transcriptional heterogeneity of NC-AML (Bullinger et al., 2004; Valk et al., 2004) .
As described previously (Virtaneva et al., 2001; Bullinger et al., 2004) , the expression profiles were more heterogeneous in tri8-AML compared to AML with translocations. We identified a set of discriminator genes characterized by an over-representation of genes mapping to chromosome 8 in tri8-AML compared to NC-AML cases. Among the four chromosome 8 genes overexpressed, NBS1 and RECQL4 encode proteins involved in homologous recombination repair of DNA double-strand damages and may act in the same pathway (Bachrati and Hickson, 2003) . It is possible that tri8-AML cases have an increased number of DNA breaks and an elevated necessity for repair. Although the discriminator genes are different, our results confirm Gene expression profiling of acute myelogenous leukaemia N Vey et al the previously reported hypothesis (Virtaneva et al., 2001 ) that a gene-dosage effect underlies the phenotypic alteration of tri8-AML.
Gene expression signature of NC-AML with FLT3 and MLL alterations Many gene alterations may be present in AML, but are not detected by conventional karyotyping. Two of these affect the FTL3 and MLL genes. We thus investigated the transcriptional impact of FLT3 and MLL duplications in NC-AML. FLT3-ITD is found in ca. 30% of adult AML and has been associated to poor prognosis (Kottaridis et al., 2001) . Among the genes identified as discriminator between FLT3-positive and FLT3-negative samples were DNCL1 that encodes a regulator of nitric oxide synthase (Jaffrey and Snyder, 1996) , genes involved in cell signalling (RIPX, PPP3CB, PME-1), and transcriptional regulators (TBX3, MYBL2). Similarly, a GES was able to classify accurately MLL-positive and MLL-negative NC-AML. Discriminator genes included MLL3, which belongs to the MLL family, and genes involved in RNA biology (HNRPH2 and TDRD3). Strikingly, several genes involved in inflammation and stress such as CHUK, HIF1A IL4R, IL16, NOS2A, and TBXA2R were overexpressed in MLL-positive patients. Relationships between thromboxane receptor and nitric oxide, and between thromboxane receptor and IL4R, have been reported (Tanaka et al., 2002; Reid and Kinsella, 2003) .
Identification of NC-AML classes with distinct prognosis
The behaviour and outcome of NC-AML are highly heterogeneous. The molecular basis of this variability remains poorly understood and standard parameters are insufficient to predict prognosis accurately. We identified a set of genes differentially expressed between the NC-AML samples from patients who achieved longterm disease-free survival after conventional treatment and those from patients with TF. The combined expression of these genes correctly classified all except two of 24 patients according to their outcome. These results are in agreement with previous studies (Okutsu et al., 2002; Yagi et al., 2003; Bullinger et al., 2004; Valk et al., 2004) .
The class with unfavourable outcome was characterized by the abnormal expression of the TOP2B and PRKAB2, and by genes encoding protein transporters (MTX2, SLC35A2). TOP2B encodes the b topoisomerase II (topo II) isoenzyme, a target of the topo II inhibitors such as anthracyclines (Kaufmann et al., 1998) . Downregulation of the two topo II isoenzymes, a and b, has been associated to resistance to topo II inhibitors (Dingemans et al., 1999) . The PRKAB2 gene encodes the b2-subunit of the AMP-activated protein kinase, which plays a role in protecting tumour cells from metabolic stress (Kato et al., 2002) . Other genes associated with poor prognosis linked to resistance include SLC35A2, which codes for an UDP-galactose transporter involved in the metabolism of topoisomerase I inhibitors (Iyer et al., 1998) , TAGLN2 (Wallqvist et al., 2003) , and MTX2, which is commonly activated following exposure to doxorubicin (Bonilla and del Mazo, 2003) .
The two prognostic NC-AML classes that we have identified also differed with regard to some clinical and biological parameters. Patients in the poor prognosis class were significantly older and showed more frequent (Pinto et al., 2001) and explain the dismal outcome of these patients. Our results indicate that this class of patients can be identified on the basis of a GES. Our results are consistent with current models of AML molecular pathogenesis that distinguish two main categories (Downing and Shannon, 2002) . One category is represented by AML with recurrent cytogenetic abnormalities such as translocations whose molecular features rely on the presence of chimaeric transcription factors associated with various cooperating mutations. The second category includes MDS-related AML, a vast and complex disease whose molecular pathology remains poorly understood. Our results suggest that the NC-AML group can be dichotomized according to this model. We have identified one subgroup close to the translocation-bearing leukaemias (the 'translocationlike' subgroup, which overlaps with our prognostic class II including young patients with favourable prognosis), while other NC-AML cases (clustered in the 'pure-NC' subgroup, which overlaps with our prognostic class I) are more analogous to the MDS-related AML phenotype and show overexpression of genes involved in drug resistance.
Materials and methods
Patients and samples
We analysed a series of 55 AML samples of leukaemic cells obtained from 53 adult patients at diagnosis (bone marrow for Multicolour fluorescence in situ hybridization (MetaSystem, GmbH, Altlussheim, Germany) and telomeric probes (ToTelVysion Probe Panel. Vysis, Voisin-le-Bretonneux, France) did not show abnormalities in all patients tested (n ¼ 13). In addition, 37 samples (24 and 13 with normal and abnormal karyotype, respectively) were tested for the presence of duplicated or mutated FLT3 as described (Noguera et al., 2002) . In all, 20 samples were also tested for the presence of duplicated MLL using RT-PCR by previously described methods (Poirel et al., 1996) . The NB4 and Kasumi cell lines, which harbour the t(15;17) and t(8;21) translocation, respectively, were obtained from Drs M Lanotte (Paris, France) (Lanotte et al., 1991) and H Drexler at the 'Deutsche Sammlung von Mikroorganismen und Zellkulturen' (http:// www.dsmz.de/). Prognostic analysis focused on 24 patients with NC-AML who could be evaluated for clinical outcome according to the following criteria: (1) assessable for response to induction chemotherapy, and (2) a minimum follow-up of 24 months for patients without relapse after CR. Among these 24 patients, six patients had primary refractory AML (defined as a failure after two induction courses), seven patients had relapsed at a median of 13 months from CR (range: 6-29 months), and 11 patients are alive in CR with a median follow-up of 39 months (range: 27-67 months). All patients received conventional anthracycline-cytarabine induction treatment according to the protocols used in our institution (Reiffers et al., 1996a, b) . Postremission treatment differed according to age: patients less than 60 years (15 patients) received one course of high-dose cytarabine (HDAC) followed by allogeneic stem cell transplantation (SCT) (four patients), autologous SCT (six patients), or a second course of HDAC (eight patients). Patients over 60 received 1-year maintenance chemotherapy (Reiffers et al., 1996a) .
RNA extraction
Total RNA was isolated from frozen samples of mononucleated cells separated upon a Ficoll gradient using guanidinium isothiocyanate solution and centrifugation on caesium chloride cushion as described (Theillet et al., 1993) . RNA integrity was controlled by electrophoresis on agarose gels and by Agilent spectrum (Bioanalyzer, Palo Alto, CA, USA).
DNA microarrays construction and hybridizations
Gene expression profiling was carried out using DiscoveryChip DNA microarrays prepared in our core facility (Ipsogen, Marseille, France; http://www.ipsogen.com). They contained 9039 IMAGE clones, including 3587 ESTs and 4540 known genes (163 Unigene release); many of them were known for their proven or putative implication in oncogenesis and immune reactions. The selection of clone was based on certain criteria: same cloning vector (pT7T3D, Lafmid BA or BlueScript) with a modified polylinker, same host bacteria (Escherichia coli DH10B), homogeneous insert size (near 1 kb), and absence of detectable repeat sequences according to the EST data available. Clones were provided by the Human Genome Mapping Project Resource Centre (Hinxton, UK). The full list of clones is available in PDF format upon request to Ipsogen (http://www.ipsogen.com). Clones were spotted as PCR products on 12 Â 8.5 cm 2 nylon filters adhered to glass slides with a Microgrid II robot (Biorobotics Apogent Discoveries, http://www.apogentdiscoveries.com/BioRobotics.asp). Microarrays included several controls clones, such as negative controls (poly(A) þ stretches of different sizes, cloning vector, negative PCR controls) and positive controls (plant cDNAs corresponding to spiked mRNAs). Microarray spotting was carried out as described (http://www.ipsogen.com). Hybridizations were carried out with radioactive [a-
33 P]dCTPlabelled probes made from 5 mg of total RNA from each sample according to described protocols (http://www.ipsogen.-com). After hybridization, membranes were washed, exposed to phosphor-imaging plates and scanned with a FUJI BAS 5000 machine at a resolution of 25 mm. Signal intensities were quantified with ArrayGauge software (Fuji, Du¨sseldorf, Germany), then normalized in two successive steps: a first normalization for the amount of spotted DNA (Bertucci et al., 2002) to ensure that each gene expression measurement is independent of this amount and a second normalization for the variability of experimental conditions using nonlinear rank-based methods (Sabatti et al., 2002) . Briefly, this consists in the selection of invariant genes between a reference array and the array to be normalized, on which a polynomial curve is calculated and subsequently applied to the whole array. The equation of this correlation curve is then applied to all clones on the array for normalization. After normalization, data were log-transformed before analysis. Microarray expression measurements are available upon request to Ipsogen (http:// www.ipsogen.com).
Data analysis and statistical methods
Genes/ESTs with expression detected in at least 80% of the hybridizations and standard deviation >2 were selected for the clustering analyses. Unsupervised hierarchical clustering was applied to data median-centred on genes using Ipsogen ProfileSoftwaret Corporate (average linkage clustering using Pearson's correlation as similarity metric). Supervised analysis aimed at identifying and ranking genes the expression of which discriminates between two groups of samples distinguished a priori by bioclinical parameters. Appropriate Student's t-test was performed for each gene, testing for the absence of differential expression between the two groups. Although we had to correct for multiple testing, Bonferroni correction was not applied, since this appears too conservative in DNA microarray experiments. Since the statistical power of the analysis depends on the number of tested samples, we applied different thresholds for statistical significance in each analysis. The less samples in one group, the more stringent was the threshold for P-value, then varying from 5 Â 10 À3 to 10 À4 . Statistical analyses were carried out using the SPSS software (version 10.0.5). Follow-up was measured from the date of diagnosis to the date of last news for live patients. Correlation between sample groups defined upon gene expression profiles and molecular and cytoclinical parameters were investigated by using the w 2 or Fisher's exact tests. All P-values were twosided at the 5% level of significance. Gene expression profiling of acute myelogenous leukaemia N Vey et al
